Date: 2015-01-08
Type of information: Treatment of the first patient
phase: 1-2
Announcement: treatment of the first patient
Company: Gamida Cell (Israel)
Product: NiCord®
Action
mechanism: cell therapy. NiCord® is derived from a single umbilical cord blood unit which has been expanded in culture and enriched with stem and progenitor cells using Gamida Cell’s proprietary NAM technology. NiCord® is in development as an investigational therapeutic treatment for blood cancers such as leukemia and lymphoma and for non-malignant hematological diseases. Clinical sites in the US, Spain, Italy, Israel and the Netherlands will collectively enroll 20 patients, with hematologic malignancies following myeloablative therapy, in the Phase I/II study of NiCord®, in a single cord configuration.
Disease: blood cancers
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On January 8, 2015, Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced that the first person has been successfully transplanted with cryopreserved (frozen) NiCord® in the company’s ongoing Phase I/II clinical study for blood cancer patients. This is the first time that a patient has been successfully transplanted with umbilical cord blood stem and progenitor cells, that were expanded (population increased) ex-vivo (outside of the body), and cryopreserved. The company also noted that after thaw, the cryopreserved product maintained the advantage of NiCord® in demonstrating very rapid engraftment (white blood cell recovery). It is expected that this rapid engraftment will reduce the risk of opportunistic infections, will lower the morbidity associated with cord blood transplantation and shorten hospitalization. NiCord® is currently manufactured and shipped to the US and Europe from Gamida Cell in Jerusalem.
